newsfilter
← Latest News
GlobeNewswire·

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – – Progression-free survival of 5.6 months in median